Literature DB >> 11678345

Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients.

G Michałowska-Wender1, J Losy, M Wender.   

Abstract

In patients suspected of multiple sclerosis (MS), even in the case of MRI positive changes, cerebrospinal fluid (CSF) analysis is of great practical value. Until now, however, only IgG index, restricted oligoclonal IgG bands and the examination of IgG subclasses have been of practical value. The determination of other immunological markers is too expensive to be introduced into laboratory diagnostic standards in MS. However, the clinical trials should be monitored by a large set of markers of MS activity, including the estimation of anti MBP antibodies, presence of MBP material in the CSF and concentration of sVCAM-1, ICAM-1, PECAM-1 in CSF and serum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678345

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  2 in total

Review 1.  Evidence from biomarkers and surrogate endpoints.

Authors:  Andrew Feigin
Journal:  NeuroRx       Date:  2004-07

2.  Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry.

Authors:  Andrew K Ottens; Erin C Golden; Liliana Bustamante; Ronald L Hayes; Nancy D Denslow; Kevin K W Wang
Journal:  J Neurochem       Date:  2007-11-22       Impact factor: 5.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.